Core Insights - Alpha Tau Medical Ltd. has announced that an abstract detailing results from two clinical trials on its alpha-radiation cancer therapy, Alpha DaRT, for pancreatic cancer has been accepted for oral presentation at Digestive Disease Week (DDW) 2026, marking a significant recognition of its technology in a major gastroenterology conference [1][2][3] Company Overview - Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of Alpha DaRT for treating solid tumors [5] - The Alpha DaRT technology was initially developed by Professors Itzhak Kelson and Yona Keisari from Tel Aviv University [5] Technology Details - Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed for highly potent and conformal alpha-irradiation of solid tumors through intratumoral delivery of radium-224 sources, aiming to primarily affect the tumor while sparing surrounding healthy tissue [6] Clinical Trial Presentation - The abstract titled "Updated Results of Feasibility, Safety, and Tumor Control in Two First-In-Human Trials of a Novel Alpha-Emitting Radionuclide for Pancreatic Adenocarcinoma" will be presented on May 2, 2026, at 10:30 am (Central) during the Pancreatic Cancer I: Diagnosis and Treatment session [2] - The presentation will be led by Dr. Harold Jacob, the Principal Investigator, and is based on combined data from two clinical protocols conducted at Hadassah Medical Center in Jerusalem [2] Significance of Presentation - The acceptance of the abstract for oral presentation at DDW is viewed as a milestone for Alpha Tau, indicating growing recognition of the potential of Alpha DaRT to address pancreatic cancer, particularly for patients deemed inoperable at diagnosis [3] - Dr. Jacob emphasized the importance of this presentation as it represents the first clinical data of Alpha DaRT in pancreatic cancer to be shared at a major gastroenterology forum [3]

Core Insights - Alpha Tau Medical Ltd. reported a strong financial position with $76.9 million in cash and equivalents, supporting clinical advancements and commercial preparations [1][12] - The company has made significant progress in clinical trials and received marketing approval in Japan, marking a pivotal moment for its Alpha DaRT technology [2][4] Financial Performance - For the year ended December 31, 2025, R&D expenses increased to $32.1 million from $27.0 million in 2024, driven by higher employee compensation, raw material costs, and contractor expenses [8] - Marketing expenses decreased to $1.9 million from $2.3 million in 2024, while G&A expenses rose to $8.4 million from $6.7 million, primarily due to increased compensation and professional fees [9] - The company reported a net loss of $42.6 million, or $0.53 per share, compared to a net loss of $31.8 million, or $0.45 per share, in 2024 [11][23] Clinical and Regulatory Developments - Alpha Tau received marketing approval in Japan for Alpha DaRT in treating unresectable locally advanced or locally recurrent head and neck cancer, requiring a post-market surveillance study [6] - The company has five clinical trials approved in the U.S., including pivotal trials for skin cancer and pancreatic cancer, with significant milestones expected in the coming months [4][5] - Positive data from pancreatic cancer trials showed a 22% objective response rate and an 81% disease control rate across 32 patients [6] Manufacturing and Strategic Initiatives - Alpha Tau announced the receipt of a radioactive material license for its New Hampshire manufacturing facility, enabling commercial-scale production of Alpha DaRT [5] - The company is focused on expanding its manufacturing capabilities and engaging in strategic dialogues with potential partners to enhance the prospects for Alpha DaRT [2]

Core Insights - Alpha Tau Medical Ltd. is preparing for a highly active clinical year in 2026, with significant patient recruitment and data readouts expected from various cancer trials, including the ReSTART pivotal trial for skin cancer and studies for internal organ cancers [1][12] Clinical Trials and Developments - The company is conducting multiple significant clinical trials globally, with five approved trials in the U.S. and additional trials in France, Italy, and the UK, focusing on various cancer types [2][3] - Ongoing trials include treatments for prostate, lung, and pancreatic tumors, as well as a pivotal trial for recurrent cutaneous squamous cell carcinoma (cSCC) [3][5] - The company is targeting completion of patient recruitment for the pancreatic cancer study by the end of Q1 2026, with initial results expected by year-end [7] - Initial results from the glioblastoma multiforme (GBM) trial are anticipated around the end of Q4 2026, with a cautious approach to patient enrollment [8] Regulatory and Commercial Readiness - Alpha Tau is awaiting a response from Japan's Ministry of Health regarding approval for Alpha DaRT in treating recurrent head and neck cancer, which would mark its first commercial approval outside Israel [9] - The company is preparing for potential post-marketing surveillance in Japan and is also exploring a new clinical trial combining Alpha DaRT with checkpoint inhibitors for advanced head and neck cancer [10] - Manufacturing capabilities are being ramped up in Jerusalem and a new facility in New Hampshire, with a focus on scaling production and enhancing operational efficiency [15][16] Financial Position and Strategic Outlook - The company maintains a stable cash burn rate and is confident in its ability to execute current plans, having filed over 60 new patent applications in 2025 [17][18] - Increased recognition of Alpha DaRT's relevance in oncology is leading to strategic discussions with potential partners for collaboration [19] - The company anticipates a busy and challenging year in 2026, building on the successes of 2025 and aiming to achieve set goals [20]

Core Insights - Alpha Tau Medical Ltd. has submitted the first module of its pre-market approval (PMA) application to the FDA for its Alpha DaRT therapy aimed at treating recurrent cutaneous squamous cell carcinoma (cSCC) [1][2] - The FDA has granted Alpha Tau a flexible modular submission framework, allowing for streamlined review and feedback as each module is submitted [1][2] - The ReSTART pivotal study, which is currently ongoing, is expected to complete patient recruitment by Q1 2026 [1][2] Company Overview - Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of Alpha DaRT for solid tumors [3] - The Alpha DaRT technology was developed by professors from Tel Aviv University and is designed for targeted alpha-irradiation of tumors [4] Technology Details - Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) utilizes radium-224 sources for intratumoral delivery, aiming to destroy tumors while sparing surrounding healthy tissue [4]

Group 1: Company Performance - Starfighters Space Inc. (AMEX:FJET) experiences a stock price drop to $14.38, reflecting a 54.32% decrease post-IPO, initially priced at $3.59 per share, indicating significant volatility [1][6] - Northann Corp. (NYSE American:NCL) sees its stock price fall to $0.13, a 48.23% decline, facing compliance issues with NYSE American regarding stockholders' equity by January 7, 2026 [2][6] - Nuvation Bio Inc. (NUVB-WT) reports a stock price decline to $0.32, a 47.24% decrease, amidst challenges in the oncology therapeutics sector [3] - X3 Holdings Co Ltd. (NASDAQ:XTKG) faces a dramatic stock price drop to $0.16, reflecting a 90.36% decrease, amid significant market challenges [4][6] Group 2: Market Sentiment and Industry Challenges - The stock movements of these companies reflect a variety of factors, including market sentiment, industry-specific challenges, and broader economic conditions [5]

Company Overview - Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of the Alpha DaRT for treating solid tumors [3] - The technology behind Alpha DaRT was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University [3] Product Information - Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed for highly potent and conformal alpha-irradiation of solid tumors through intratumoral delivery of radium-224 impregnated sources [4] - The therapy aims to destroy tumors while sparing surrounding healthy tissue, as the alpha-emitting atoms diffuse only a short distance [4] Upcoming Events - Alpha Tau will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026, at 11:15 AM PT / 2:15 PM ET in San Francisco, CA [1] - The presentation will include a review of recent achievements and the outlook for upcoming data milestones [1] - Institutional investor meetings will also be hosted at the event, and a webcast link will be available on the company's Investor Relations page [2]

Core Viewpoint - Alpha Tau Medical Ltd. has successfully treated the first patient in the world with its Alpha DaRT technology for recurrent glioblastoma multiforme (GBM), marking a significant milestone in cancer treatment [3][4]. Company Overview - Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of Alpha DaRT for solid tumors [9]. - The Alpha DaRT technology was initially developed by professors from Tel Aviv University [9]. Technology Details - Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) utilizes intratumoral delivery of radium-224 sources to emit high-energy alpha particles, aiming to destroy tumors while sparing surrounding healthy tissue [10]. - The technology is designed to provide highly potent and conformal alpha-irradiation specifically targeting solid tumors [10]. Clinical Study Insights - The pilot study aims to enroll up to ten U.S. patients with recurrent glioblastoma who are not suitable for surgical resection and have previously undergone central nervous system radiation [8]. - The primary objective of the study is to evaluate the feasibility and safety of the Alpha DaRT treatment, following promising preclinical results [8]. Treatment Significance - The treatment of GBM patients with Alpha DaRT addresses a critical need for new local therapies, given the high recurrence rate of GBM, typically within 6-9 months [4][6]. - The procedure demonstrated excellent feasibility, achieving over 95% coverage of the tumor volume with a novel delivery device that integrates seamlessly into standard neurosurgical workflows [7].

Core Insights - Alpha Tau Medical Ltd. is advancing its innovative alpha-radiation cancer therapy, Alpha DaRT, with a multi-center clinical trial for pancreatic cancer in the U.S. expected to complete patient recruitment by the end of Q1 2026 [1][2] - The company will present two abstracts at the 2026 ASCO Gastrointestinal Cancers Symposium, showcasing data from its recently completed pilot trial in Montreal [1][2] Company Overview - Alpha Tau Medical Ltd. was founded in 2016 and focuses on the research, development, and potential commercialization of Alpha DaRT for treating solid tumors [4] - The technology was developed by professors from Tel Aviv University, emphasizing its academic foundation [4] Clinical Trial Details - The U.S. multi-center pancreatic cancer clinical trial began patient treatment in September 2025 and aims to enroll up to 30 patients with newly diagnosed pancreatic cancer [2] - Approximately 87% of newly diagnosed pancreatic cancer patients are deemed inoperable, highlighting the significant unmet medical need [2] Technology Description - Alpha DaRT utilizes radium-224 for intratumoral delivery, allowing for targeted alpha-irradiation of solid tumors while minimizing damage to surrounding healthy tissue [3]

Core Viewpoint - Alpha Tau Medical Ltd. has received FDA approval for a pilot study using its Alpha DaRT technology to treat locally recurrent prostate cancer, marking its fifth active Investigational Device Exemption (IDE) in the U.S. [1][3] Group 1: Company Developments - The FDA's approval allows Alpha Tau to expand its Alpha DaRT technology into the U.S. market for prostate cancer treatment [1] - The clinical trial will enroll up to 12 patients with locally recurrent prostate cancer, focusing on safety and efficacy evaluations [2] - Alpha Tau aims to provide a new local salvage therapy option for patients facing limited alternatives [3] Group 2: Technology Overview - Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) utilizes radium-224 to deliver targeted alpha-radiation to solid tumors, minimizing damage to surrounding healthy tissue [4] - The technology was developed by researchers from Tel Aviv University and is focused on treating solid tumors [5]

Company Overview - Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of the Alpha DaRT for treating solid tumors [3] - The technology behind Alpha DaRT was developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University [3] Product Information - Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed for highly potent and conformal alpha-irradiation of solid tumors through the intratumoral delivery of radium-224 impregnated sources [4] - The therapy aims to destroy tumors while sparing surrounding healthy tissue, as the alpha-emitting atoms diffuse only a short distance [4] Upcoming Events - CFO Raphi Levy will present at the 37th Annual Piper Sandler Healthcare Conference on December 3, 2025, from 1:00 to 1:25 PM ET in New York, NY [2] - Mr. Levy will also present at Sidoti's Year End Virtual Investor Conference on December 10, 2025, from 11:30 AM to 12:00 PM ET [2] - Mr. Levy will be available for one-on-one investor meetings at both conferences [2]